| Spirig HealthCare AG - Oyavas 400 mg/16 ml, Konzentrat zur Herstellung einer Infusionslösung |
| 67857 | | 02 | | Oyavas 400 mg/16 ml | | Konzentrat zur Herstellung einer Infusionslösung | | L01FG01 | | Bevacizumab | | 04.06.2021 | | |
|
| Composition |
| bevacizumabum 400 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20 6.4 mg, aqua ad iniectabile q.s. ad solutionem pro 16 ml corresp. natrium 21.68 mg. |
| Packungsbestandteile |
| Concentrate for infusion | | | | | | | | Active Agent | Dose |
|---|
| Bevacizumab | 400mg / 16ml |
| | BAG: Active Agent | Dose |
|---|
| Bevacizumab | 400 mg |
| | | | Inactive agents | Dose |
|---|
| Disodium Phosphate | | | Sodium Dihydrogenophosphate Monohydrate | | | Polysorbatum 20 | 6.4mg / 16ml | | Trehalosum Dihydricum | |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 002 | | 827.41 | 924.60 | A | SL | No |
|
